Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChristina Berr. MD

About this trial

Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

persistent atrial fibrillation, eligible for ablation

BMI 19-40

Disqualifiers

valvular atrial fibrillation

formerly ablation

medication interfereing with measurements of atrial fibrosis

known or treated comorbidities (OSAS, PA)

Trial population

Patients with persistent atrial fibrillation, eligible for ablation

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Screening on comorbidites

    Diagnostic test

    Patients with persistent atrial fibrillation that undergo ablation are screened for comorbidities

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

quantification of area of left-atrial fibrosis in the heart

During ablation elecrical maping of the left-atrium is done and percentage of left-atrial fibrosis (electrical tissue abnormalities) will be assessed

Time frame
baseline
2

Rate of recurrence of atrial fibrillation (yes/no) in the study group

measure the recurrence of AF in follow-up with holter-ekgs

Time frame
1 year after procedure (ablation)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Christina Berr. MD

Lead sponsor

University Hospital Augsburg

Sponsor institution